A groundbreaking study reveals how targeting two enzymes, PDIA1 and PDIA5, can weaken prostate cancer cells, enhancing the effectiveness of existing treatments like enzalutamide and improving survival rates.
Earl Vickers, a 69-year-old retired engineer, shares how stopping his prostate cancer medication, enzalutamide, dramatically improved his stability and prevented falls. Discover the alarming statistics on falls among older adults and the importance of medication side effects.
